866-997-4948(US-Canada Toll Free)

Fabry Disease-Market Insights, Epidemiology and Market Forecast-2025

Published By :

DelveInsight

Published Date : Sep 2017

Category :

Pharmaceutical

No. of Pages : 70 Pages

DelveInsights Fabry Disease-Market Insights, Epidemiology and Market Forecast-2025 report provides an overview of the disease and in depth research related to Fabry Disease for the 7MM (United States, Germany, France, Italy, Spain and UK) for the study period undertaken from 2015-2025. This report provides understanding of the patients affected, diagnosed patterns, treatment trends, unmet medical needs and current developments for Fabry Disease . It enables understanding of the historical and forecasted epidemiological data for the diagnosed prevalent cases of Fabry Disease for 7 major markets.

The market outlook also provides understanding of country specific revenue and share by analyzing performance of the current therapies and thorough potential uptake of new products. Additionally, the Report highlights the frontrunners, the drivers and barriers for the Fabry Disease market, as well as treatment algorithm, current treatments & advancements are included.The chapters including marketed products highlights the advantages and disadvantages associated with therapies associated with Fabry Disease , providing an in-depth analysis of emerging therapies which will create an impact through their launch.

According to DelveInsight, the forecasted patient population of Fabry Disease for the year 2025 will be XX, increasing at a CAGR of XX% from 2015 to 2025 and the Fabry Disease 7MM market size is estimated to be USD XX by 2025.The DelveInsight Report will help in enhanced understanding of the Fabry Disease market from inside out, with transparency into the calculated patient forecasting data and estimated market size.

Key Coverage

Understanding historical and forecasted epidemiological data for Fabry Disease covering 7MM from 2015-2025.
Segment level epidemiology and market split for Fabry Disease .
The thorough assessment of competitors, market, current trends & treatments along with upcoming treatments for Fabry Disease .
The Report also covers the market size for 7MM (United States, EU 5 (Germany, Spain, Italy, France and United Kingdom) and Japan) from 2015-2025 and detailed historical and forecasted Fabry Disease market trends.
Thorough market distribution based on market share for Fabry Disease .

Reasons to buy

The report will help in developing business strategies by understanding trends shaping and driving the Fabry Disease market.
To understand the future market competition in the Fabry Disease market and Insightful review of the key market drivers and barriers.
Organize sales and marketing efforts by identifying the best opportunities for Fabry Disease in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan.
Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors.

1. Report Introduction
1.1.1. Anderson-Fabry Disease Market Overview at a Glance
1.1.2. Market Share Distribution of Anderson-Fabry Disease in 2016
1.1.3. Market Share Distribution of Anderson-Fabry Disease in 2025
1.1.4. Total Market by Region of Anderson-Fabry Disease (2016 & 2025)
2. Disease Background and Overview
3. Introduction
3.1.1. Timeline for Anderson-Fabry Disease
3.1.2. Classification
3.1.3. Signs and Symptoms
3.1.4. Etiology
3.1.5. Inheritance Pattern
3.1.6. Pathophysiology
3.1.7. Diagnosis
3.1.8. European Fabry Working Group (EFWG): Diagnostic criteria
3.1.9. Challenges in Diagnosis
3.1.10. Expert Opinions Regarding Diagnosis of Fabry Disease
4. Epidemiology and Patient Population
4.1.1. Prevalent Population of Anderson-Fabry Disease in 7MM
4.1.2. Prevalent Population of Anderson-Fabry Disease in 7MM-By Region
4.1.3. Prevalent Population of Anderson-Fabry Disease in 7MM-Distribution (2016)
4.1.4. Prevalent Population of Anderson-Fabry Disease in 7MM-Distribution (2025)
4.1.5. United States
4.1.6. Prevalent Population of Anderson-Fabry Disease
4.1.7. Sex-Specific Prevalent Population of Anderson-Fabry Disease
4.1.8. Sub-type Specific Prevalent Population of Anderson-Fabry Disease
4.1.9. EU5 countries
4.1.10. Germany
4.1.11. Prevalent Population of Anderson-Fabry Disease
4.1.12. Sex-Specific Prevalent Population of Anderson-Fabry Disease
4.1.13. Sub-type-Specific Prevalent Population of Anderson-Fabry Disease
4.1.14. France
4.1.15. Prevalent Population of Anderson-Fabry Disease
4.1.16. Sex-Specific Prevalent Population of Anderson-Fabry Disease
4.1.17. Sub-type Specific Prevalent Population of Anderson-Fabry Disease
4.1.18. United Kingdom
4.1.19. Prevalent Population of Anderson-Fabry Disease
4.1.20. Sex-Specific Prevalent Population of Anderson-Fabry Disease
4.1.21. Sub-type Specific Prevalent Population of Anderson-Fabry Disease
4.1.22. Spain
4.1.23. Prevalent Population of Anderson-Fabry Disease
4.1.24. Sex-Specific Prevalent Population of Anderson-Fabry Disease
4.1.25. Sub-type Specific Prevalent Population of Anderson-Fabry Disease
4.1.26. Italy
4.1.27. Prevalent Population of Anderson-Fabry Disease
4.1.28. Sex-Specific Prevalent Population of Anderson-Fabry Disease
4.1.29. Sub-type Specific Prevalent Population of Anderson-Fabry Disease
4.1.30. Japan
4.1.31. Prevalent Population of Anderson-Fabry Disease
4.1.32. Sex-Specific Prevalent Population of Anderson-Fabry Disease
4.1.33. Sub-type Specific Prevalent Population of Anderson-Fabry Disease
5. Treatment Practices
6. Treatment Goals
7. Treatment Algorithm
7.1.1. Guidelines for management of Fabry Disease
7.1.2. Croatian Society: Recommendation for the treatment of Fabry Disease
7.1.3. Expert Opinions Regarding the Treatment of Fabry Disease
8. Marketed Drugs List
9. Marketed Drugs
9.1.1. Galafold: Amicus Therapeutics, Inc.
9.1.2. Drug Description
9.1.3. Mechanism of Action
9.1.4. Regulatory Milestones
9.1.5. Advantages & Disadvantages
9.1.6. Safety and Efficacy
9.1.7. Product Profile
9.1.8. Side-Effects
9.1.9. Drug Sales
9.1.10. Replagal: Shire Plc.
9.1.11. Drug Description
9.1.12. Mechanism of Action
9.1.13. Regulatory Milestones
9.1.14. Advantages & Disadvantages
9.1.15. Safety and Efficacy
9.1.16. Product Profile
9.1.17. Side-Effects
9.1.18. Drug Sales
9.1.19. Fabrazyme: Sanofi-Aventis
9.1.20. Drug Description
9.1.21. Mechanism of Action
9.1.22. Regulatory Milestones
9.1.23. Advantages & Disadvantages
9.1.24. Safety and Efficacy
9.1.25. Product Profile
9.1.26. Side-Effects
9.1.27. Drug Sales
9.1.28. Emerging Therapies
9.1.29. Phase-III Drugs Analysis
9.1.30. Expert commentary for Key Emerging Drugs
9.1.31. Phase III and Filed Drugs
9.1.32. Migalastat: Amicus Therapeutics Inc.
9.1.33. Regulatory Milestones
9.1.34. Other development activities
9.1.35. Clinical Development
9.1.36. Clinical Trials Information
9.1.37. Safety and Efficacy
9.1.38. Advantages and Disadvantages
9.1.39. Product Profile
9.1.40. PRX-102: Protalix Biotherapeutics
9.1.41. Regulatory Milestones
9.1.42. Other development activities
9.1.43. Clinical Development
9.1.44. Ongoing Trials Information
9.1.45. Safety and Efficacy
9.1.46. Advantages and Disadvantages
9.1.47. Product Profile
9.1.48. Phase II Drugs
9.1.49. GZ/SAR402671: Sanofi-Aventis
9.1.50. Regulatory Milestones
9.1.51. Other development activities
9.1.52. Clinical Development
9.1.53. Clinical Trials Information
9.1.54. Product Profile
9.1.55. Current Unmet Need
10. Anderson-Fabry Disease: Market Analysis
10.1.1. Market Outlook: Global
10.1.2. Market size of Anderson-Fabry Disease-Global (2015-2025)
10.1.3. Market Outlook: 7Major Markets
10.1.4. Market size of Anderson-Fabry Disease in 7MM (2016)
10.1.5. Market size of Anderson-Fabry Disease in 7MM (2025)
10.1.6. Market size of Anderson-Fabry Disease in 7MM
11. Market Outlook
11.1.1. US Market size
11.1.2. Market size by Drug Administration
11.1.3. Anderson-Fabry Disease: EU5
12. Market Outlook
12.1.1. Germany Market size
12.1.2. Market size by Drug Administration
12.1.3. France Market size
12.1.4. Market size by Drug Administration
12.1.5. United Kingdom Market size
12.1.6. Market size by Drug Administration
12.1.7. Spain Market size
12.1.8. Market size by Drug Administration
12.1.9. Italy Market size
12.1.10. Market size by Drug Administration
13. Anderson-Fabry Disease: Japan Market Outlook
13.1.1. Japan Market size
13.1.2. Market size by Drug Administration
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
18. Consulting Services
19. Disclaimer
20. About DelveInsight

List of Table

Table 1: Pathophysiologic findings in Anderson-Fabry Disease
Table 2: Proposed assessments for Anderson-Fabry Disease
Table 3: Clinical evaluation and monitoring of adult patients with Fabry Disease
Table 4: Clinical evaluation and monitoring of pediatric patients with Fabry Disease
Table 5: Diagnostic criteria of European Fabry Working Group (EFWG)
Table 6: Fabry disease: Common misdiagnoses
Table 7: Prevalent Population of Anderson-Fabry Disease in 7MM (2015-2025)
Table 8: Prevalent Population of Anderson-Fabry Disease in 7MM (2015-2025)
Table 9: Prevalent Population of Anderson-Fabry Disease in United States (2015-2025)
Table 10: Sex-Specific Prevalent Population of Anderson-Fabry Disease in United States (2015-2025)
Table 11: Sub-type Specific Prevalent Population of Anderson-Fabry Disease in United States (2016)
Table 12: Prevalent Population of Anderson-Fabry Disease in Germany (2015-2025)
Table 13: Sex-Specific Prevalent Population of Anderson-Fabry Disease in Germany (2015-2025)
Table 14: Sub-type Specific Prevalent Population of Anderson-Fabry Disease in Germany (2016)
Table 15: Prevalent Population of Anderson-Fabry Disease in France (2015-2025)
Table 16: Sex-Specific Prevalent Population of Anderson-Fabry Disease in France (2015-2025)
Table 17: Sub-type Specific Prevalent Population of Anderson-Fabry Disease in France (2016)
Table 18: Prevalent Population of Anderson-Fabry Disease in United Kingdom (2015-2025)
Table 19: Sex-Specific Prevalent Population of Anderson-Fabry Disease United Kingdom (2015-2025)
Table 20: Sub-type Specific Prevalent Population of Anderson-Fabry Disease in United Kingdom (2016)
Table 21: Prevalent Population of Anderson-Fabry Disease in Spain (2015-2025)
Table 22: Sex-Specific Prevalent Population of Anderson-Fabry Disease in Spain (2015-2025)
Table 23: Sub-type Specific Prevalent Population of Anderson-Fabry Disease in Spain (2016)
Table 24: Prevalent Population of Anderson-Fabry Disease in Italy (2015-2025)
Table 25: Sex-Specific Prevalent Population of Anderson-Fabry Disease in Italy (2015-2025)
Table 26: Sub-type Specific Prevalent Population of Anderson-Fabry Disease in Italy (2016)
Table 27: Prevalent Population of Anderson-Fabry Disease in Japan (2015-2025)
Table 28: Sex-Specific Prevalent Population of Anderson-Fabry Disease in Japan (2015-2025)
Table 29: Sub-type Specific Prevalent Population of Anderson-Fabry Disease in Japan (2016)
Table 30: Treatment goals for Fabry Disease patients associated with other conditions
Table 31: Effect of enzyme replacement therapy on signs and Symptoms of Fabry Disease
Table 32: Enzyme Replacement Therapy
Table 33:Recommended analgesic drugs for supportive treatment of Chronic neuropathic pain in Fabry Disease
Table 34:Recommended analgesic drugs for supportive treatment of acute pain in Fabry Disease
Table 35: Current guidelines for instituting enzyme replacement therapy in Fabry Disease patients
Table 36: Adjunctive therapies and preventive measures in Fabry Disease patients for common Fabry related morbidities
Table 37: Implications for Recommendations
Table 38: List of Marketed Drugs for Disease
Table 39:Comparison of Phase-III drugs under development
Table 40:Phase-III drugs :Safety and Efficacy
Table 41: Expert commentary for Key Emerging Drugs
Table 42:Migalastat, Clinical Trial Description, 2017
Table 43: PRX-102, Clinical Trial Description, 2017
Table 44: GZ/SAR402671, Clinical Trial Description, 2017
Table 45: Global Market Size of Anderson-Fabry Disease in USD Million (2015-2025)
Table 46: 7 Major Market Size of Anderson-Fabry Disease in USD Million (2015-2025)
Table 47: Market Size of Anderson-Fabry Disease in United States, USD Millions (2015-2025)
Table 48: Market Size by Drug Administration of Anderson-Fabry Disease in United States, USD Millions (2015-2025)
Table 49: Market Size of Anderson-Fabry Disease in Germany , USD Million (2015-2025)
Table 50: Market Size by Drug Administration of Anderson-Fabry Disease in Germany, USD Millions (2015-2025)
Table 51: Market Size of Anderson-Fabry Disease in France, USD Million (2015-2025)
Table 52: Market Size by Drug Administration of Anderson-Fabry Disease in France, USD Millions (2015-2025)
Table 53: Market Size of Anderson-Fabry Disease in United Kingdom, USD Million (2015-2025)
Table 54: Market Size by Drug Administration of Anderson-Fabry Disease in United Kingdom, USD Millions (2015-2025)
Table 55: Market Size of Anderson-Fabry Disease in Spain , USD Million (2015-2025)
Table 56: Market Size by Drug Administration of Anderson-Fabry Disease in Spain, USD Millions (2015-2025)
Table 57: Market Size of Anderson-Fabry Disease in Italy, USD Million (2015-2025)
Table 58: Market Size by Drug Administration of Anderson-Fabry Disease in Italy, USD Millions (2015-2025)
Table 59:Market Size of Anderson-Fabry Disease in Japan , USD Million (2015-2025)
Table 60:Market Size by Drug Administration of Anderson-Fabry Disease in Japan, USD Millions (2015-2025)

List of Chart

Figure 1: Timeline for Anderson-Fabry Disease
Figure 2: Characteristics of Type 1 classic and Type 2 later-onset Anderson-Fabry Disease
Figure 3: Symptoms of Anderson-Fabry Disease in Adults, Childhood and Adolescence
Figure 4: Inheritance Pattern of Anderson-Fabry Disease
Figure 5: Genetic and molecular basis of Anderson-Fabry Disease
Figure 6: Diagnosis Algorithm for Anderson-Fabry Disease
Figure 7: Prevalent Population of Anderson-Fabry Disease in 7MM (2015-2025)
Figure 8: Prevalent Population of Anderson-Fabry Disease in 7MM (2015-2025)
Figure 9: Prevalent Population of Anderson-Fabry Disease in United States (2015-2025)
Figure 10: Sex-Specific Prevalent Population of Anderson-Fabry Disease in United States (2015-2025)
Figure 11: Sub-type Specific Prevalent Population of Anderson-Fabry Disease in United States (2016)
Figure 12: Prevalent Population of Anderson-Fabry Disease in Germany (2015-2025)
Figure 13: Sex-Specific Prevalent Population of Anderson-Fabry Disease in Germany (2015-2025)
Figure 14: Sub-type Specific Prevalent Population of Anderson-Fabry Disease in Germany (2016)
Figure 15: Prevalent Population of Anderson-Fabry Disease in France (2015-2025)
Figure 16: Sex-Specific Prevalent Population of Anderson-Fabry Disease in France (2015-2025)
Figure 17: Sub-type Specific Prevalent Population of Anderson-Fabry Disease in France (2016)
Figure 18: Prevalent Population of Anderson-Fabry Disease in United Kingdom (2015-2025)
Figure 19: Sex-Specific Prevalent Population of Anderson-Fabry Disease in United Kingdom (2015-2025)
Figure 20: Sub-type Specific Prevalent Population of Anderson-Fabry Disease in United Kingdom (2016)
Figure 21: Prevalent Population of Anderson-Fabry Disease in Spain (2015-2025)
Figure 22: Sex-Specific Prevalent Population of Anderson-Fabry Disease in Spain (2015-2025)
Figure 23: Sub-type Specific Prevalent Population of Anderson-Fabry Disease in Spain (2016)
Figure 24: Prevalent Population of Anderson-Fabry Disease in Italy (2015-2025)
Figure 25: Sex-Specific Prevalent Population of Anderson-Fabry Disease in Italy (2015-2025)
Figure 26: Sub-type Specific Prevalent Population of Anderson-Fabry Disease in Italy (2016)
Figure 27: Prevalent Population of Anderson-Fabry Disease in Japan (2015-2025)
Figure 28: Sex-Specific Prevalent Population of Anderson-Fabry Disease in Japan (2015-2025)
Figure 29: Sub-type Specific Prevalent Population of Anderson-Fabry Disease in Japan (2016)
Figure 30: Treatment Algorithm for Anderson-Fabry Disease
Figure 31: Current Unmet Needs of Anderson-Fabry Disease
Figure 32: Global Market Size of Anderson-Fabry Disease in USD Million (2015-2025)
Figure 33: 7 Major Market Size of Anderson-Fabry Disease in USD Million (2015-2025)
Figure 34: Market Size of Anderson-Fabry Disease in United States, USD Millions (2015-2025)
Figure 35: Market Size by Drug Administration of Anderson-Fabry Disease in United States, USD Millions (2015-2025)
Figure 36: Market Size of Anderson-Fabry Disease in Germany , USD Million (2015-2025)
Figure 37: Market Size by Drug Administration of Anderson-Fabry Disease in Germany, USD Millions (2015-2025)
Figure 38: Market Size of Anderson-Fabry Disease in France, USD Million (2015-2025)
Figure 39: Market Size by Drug Administration of Anderson-Fabry Disease in France, USD Millions (2015-2025)
Figure 40: Market Size of Anderson-Fabry Disease in United Kingdom, USD Million (2015-2025)
Figure 41: Market Size by Drug Administration of Anderson-Fabry Disease in United Kingdom, USD Millions (2015-2025)
Figure 42: Market Size of Anderson-Fabry Disease in Spain, USD Million (2015-2025)
Figure 43: Market Size by Drug Administration of Anderson-Fabry Disease in Spain, USD Millions (2015-2025)
Figure 44: Market Size of Anderson-Fabry Disease in Italy, USD Million (2015-2025)
Figure 45: Market Size by Drug Administration of Anderson-Fabry Disease in Italy, USD Millions (2015-2025)
Figure 46:Market Size of Anderson-Fabry Disease in Japan, USD Million (2015-2025)
Figure 47:Market Size by Drug Administration of Anderson-Fabry Disease in Japan, USD Millions (2015-2025)

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *